Drug Profile


Alternative Names: BAY86-5044; K-230211; ZK 230211; ZK-PRA

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antiprogestogens
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Dysmenorrhoea; Endometriosis

Most Recent Events

  • 05 Apr 2011 Bayer Healthcare Pharmaceuticals completes a phase II trial in Breast cancer (metastatic disease) in Europe (NCT00555919)
  • 14 Oct 2009 Discontinued - Preclinical for Dysmenorrhoea in Germany (PO)
  • 14 Oct 2009 Discontinued - Preclinical for Dysmenorrhoea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top